Indirect costs assessment and intangible costs description of rheumatoid arthritis patients with biological therapy in Morocco: ECORAM Study.


Journal

International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930

Informations de publication

Date de publication:
Oct 2024
Historique:
revised: 30 07 2024
received: 20 02 2024
accepted: 25 09 2024
medline: 7 10 2024
pubmed: 7 10 2024
entrez: 7 10 2024
Statut: ppublish

Résumé

The aims of study are to estimate the indirect costs and intangible costs of RA in Morocco and to identify the factors likely to influence these costs among suffering patients. In the current study, data were collected by face-to-face interviews using a questionnaire in addition to the patient's files. Indirect costs including productivity losses and formal care, and intangible costs such as the cessation of physical and leisure activities, family care and divorce or remaining single until menopause's age for women due to the disease were reported for 110 RA patients. The results show that among patients who lost totally or partially their salary, the annual average costs is $2337.73 ± 1649.80 per patient, with a minimum and a maximum of $600 and $9630 respectively. As regards formal care, only 13 patients reported that they paid for care services; the annual average cost was $421.84 ± 261.34 with a minimum of $252 and a maximum of $1200. Statistical analysis revealed significant differences between annual lost salary and gender (p = .04) disease duration (p = .016) and sport/leisure activities cessation (p = .08). Besides the burden in terms of productivity loss and caregivers' costs, the intangible costs are considerable, especially those related to divorce and spinsterhood. These conclusions may contribute to the understanding of the socio-economic impact of the disease and to the development of strategies for better governance of RA in Morocco.

Identifiants

pubmed: 39373088
doi: 10.1111/1756-185X.15367
doi:

Substances chimiques

Biological Products 0
Antirheumatic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e15367

Informations de copyright

© 2024 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Références

Smith MH, Berman JR. What is rheumatoid arthritis? JAMA. 2022;327(12):1194. doi:10.1001/jama.2022.0786
Lundkvist J, Kastäng F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ. 2008;8(S2):49‐60. doi:10.1007/s10198-007-0088-8
Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine. 2004;71(6):518‐524. doi:10.1016/j.jbspin.2004.01.003
Leardini G, Salaffi F, Montanelli R, Gerzeli S, Canesi B. A multicenter cost‐of‐illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol. 2002;20(4):505‐516.
Riitta A, Aho K, Isomäki HA. Mortality in rheumatoid arthritis. Semin Arthritis Rheum. 1995;25(3):193‐202. doi:10.1016/S0049-0172(95)80031-X
Naz SM, Symmons DPM. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):871‐883. doi:10.1016/j.berh.2007.05.003
Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the global burden of disease study 2017. Ann Rheum Dis. 2019;78(11):1463‐1471. doi:10.1136/annrheumdis-2019-215920
March L, Lapsley H. What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis? Best Pract Res Clin Rheumatol. 2001;15(1):171‐185.
Rkain H, Allali F, Jroundi I, Hajjaj‐Hassouni N. Socioeconomic impact of rheumatoid arthritis in Morocco. Joint Bone Spine. 2006;73(3):278‐283. doi:10.1016/j.jbspin.2005.03.021
Batko B, Rolska‐Wójcik P, Władysiuk M. Indirect costs of rheumatoid arthritis depending on type of treatment—a systematic literature review. Int J Environ Res Public Health. 2019;16(16):2966. doi:10.3390/ijerph16162966
Yassine A, Hangouche AJ, Malhouf NE, Maarouf S, Taoufik J. Assessment of the medical expenditure of the basic health insurance in Morocco. Pan Afr Med J. 2020;35(115). doi:10.11604/pamj.2020.35.115.13076
Mouhdi H. Revue de la stratégie de financement de la Couverture médicale de Base, Au Maroc. JMSM. 2016;20(4). doi:10.48401/IMIST.PRSM/jmsm-v20i4.7947
Le premier ministre. Décret n° 2–05‐733 du 11 joumada II 1426 (18 juille t 2005) pris pour l'application de la loi n° 65–00 portant code de la couverture mé dicale de base. 2005 Accessed July 16, 2024. https://www.sante.gov.ma/Reglementation/ASSURANCEMALADIE/2‐05‐733.pdf
Karsi M, Bennana A. Etude du contexte de la gouvernance du système la couverture médicale de base au Maroc. JMSM. 2017;21(3). doi:10.48401/IMIST.PRSM/jmsm-v21i3.12520
Moustatraf A, Taoufik J. For sustainable financing of the medical assistance scheme in Morocco. Sante Publique. 2018;30(6):859‐868. doi:10.3917/spub.187.0859
Moustatraf A, Touhami F. L'identifiant unique comme un des instruments indispensables au pilotage de la couverture sanitaire universelle, le cas du Maroc. Sante Publique. 2024;36(1):121‐133. doi:10.3917/spub.241.0121
Arnett FC, Edworthy SM, Bloch DA, et al. The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315‐324. doi:10.1002/art.1780310302
Pisetsky DS. Advances in the treatment of rheumatoid arthritis: costs and challenges. N C Med J. 2017;78(5):337‐340. doi:10.18043/ncm.78.5.337
Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis. 2005;64(7):995‐1002.
de Azevedo ABC, Ferraz MB, Ciconelli RM. Indirect costs of rheumatoid arthritis in Brazil. Value Health. 2008;11(5):869‐877. doi:10.1111/j.1524-4733.2008.00332.x
Ruof J, Hülsemann JL, Mittendorf T, et al. Costs of rheumatoid arthritis in Germany: a micro‐costing approach based on healthcare payer's data sources. Ann Rheum Dis. 2003;62(6):544‐549. doi:10.1136/ard.62.6.544
Franke LC, Ament AJ, van de Laar MA, Boonen A, Severens JL. Cost‐of‐illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009;27(4 Suppl 55):S118‐S123.
Xu C, Wang X, Mu R, et al. Societal costs of rheumatoid arthritis in China: a hospital‐based cross‐sectional study. Arthritis Care Res. 2014;66(4):523‐531.
Lajas C, Abasolo L, Bellajdel B, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence‐based study. Arthritis Care Res. 2003;49(1):64‐70. doi:10.1002/art.10905
Hamuryudan V, Direskeneli H, Ertenli I, et al. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey. Clin Exp Rheumatol. 2016;34(6):1033‐1037.
Osiri M, Maetzel A, Tugwell P. The economic burden of rheumatoid arthritis in a developing nation: results from a one‐year prospective cohort study in Thailand. J Rheumatol. 2007;34(1):57‐63.
Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006;65(9):1175‐1183. doi:10.1136/ard.2005.046367
Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis. 2004;63(4):395‐401. doi:10.1136/ard.2003.006031
Birnbaum H, Pike C, Kaufman R, Maynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010;26(1):77‐90.
Boonen A, Severens JL. The burden of illness of rheumatoid arthritis. Clin Rheumatol. 2011;30:3‐8.
Hu H, Luan L, Yang K, Li SC. Burden of rheumatoid arthritis from a societal perspective: a prevalence‐based study on cost of this illness for patients in China. Int J Rheum Dis. 2018;21(8):1572‐1580. doi:10.1111/1756-185X.13028

Auteurs

Hanae Zarrik (H)

Research Team of Pharmacoeconomics and Pharmacoepidemiology, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.

Abha Cherkani Hassani (AC)

Laboratory of analytical chemistry, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.

Hanane Rkain (H)

Department of Rheumatology B, El Ayachi Hospital, Ibn Sina University Hospital, Salé, Morocco.
Physiology laboratory; Faculty of Medicine and Pharmacy of Rabat, Mohammed V University in Rabat, Rabat, Morocco.

Fadoua Allali (F)

Department of Rheumatology B, El Ayachi Hospital, Ibn Sina University Hospital, Salé, Morocco.

Rachid Bahiri (R)

Department of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, Morocco.

Samir Ahid (S)

Research Team of Pharmacoeconomics and Pharmacoepidemiology, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
Euromed Faculty of Pharmacy, Euromed University of Fes (UEMF), Fez, Morocco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH